PhRMA Names Charles Clapton, Senior Vice President, Federal Advocacy
Chuck Clapton joins PhRMA as SVP of Federal Advocacy
Washington, DC (February 25, 2014) – The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today the appointment of Charles “Chuck” Clapton to the position of Senior Vice President, Federal Advocacy, effective March 17, 2014.
In this capacity, Clapton will be responsible for leading PhRMA’s federal government affairs initiatives and advancing its legislative agenda, working with a wide array of stakeholders to develop and advocate for health policies that foster innovation and ensure patient access to new medicines in the US and around the world. He will report to Chip Davis, Executive Vice President, Advocacy and Member Relations.
“Chuck is a dynamic advocate and an expert on the policy issues facing the biopharmaceutical sector and the patients we serve,” said John J. Castellani, President and CEO of PhRMA. “He will make important contributions to our work with policymakers on promoting research and innovation and making progress for patients.”
Most recently, Clapton worked as a partner at the international law firm HoganLovells, where he represented health care clients on legislative and regulatory matters. Prior to joining HoganLovells, Clapton worked for 17 years on Capitol Hill, where he held several leadership positions on the House Energy & Commerce Committee, Ways & Means Committee, Office of the Speaker and the Senate Health, Education, Labor and Pensions Committee.
“Chuck’s experience, reputation, and results-oriented focus during his distinguished career on Capitol Hill will be tremendous assets to PhRMA and its members as he leads our Federal Advocacy efforts” said Davis. “We are thrilled to welcome Chuck to our team.”
During his time with the House and Senate, Clapton worked on reimbursement and coverage initiatives, including the Medicare Modernization Act that created the highly successful Medicare Part D drug program. In addition, he has extensive experience with policy issues related to Food and Drug Administration (FDA) review and approval of new medicines, the distribution and use of non-FDA approved drugs, and other critical patient safety matters.
“I am incredibly excited to join the PhRMA team” Clapton said. “While the industry faces significant challenges, PhRMA member companies are developing new treatments that will revolutionize how we treat diseases like cancer and diabetes. I look forward to representing PhRMA members and assisting their efforts to help patients improve access to new treatments and support policies foster the continuing development of new treatments and cures.”
Clapton earned his J.D. from the Catholic University, Columbus School of Law and B.A. from Boston College.